Skip to main content

Trevi Therapeutics, Inc. (TRVI) Stock

Trevi Therapeutics, Inc. Stock Details, Movements and Public Alerts

Stock Details

Trevi Therapeutics, Inc. (TRVI), a prominent company in the healthcare sector within the biotechnology industry, is based in United States and primarily trades on the NGM.Currently, the stock is trading at $11.44. Over the past 52 weeks, it has ranged between $3.47 and $14.39. This places the current price at 79.5% of its 52-week high and 229.5% above its 52-week low. Recent trading volume was recorded at 1,315,186. The 14-day Relative Strength Index (RSI) stands at 43.15, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $12.09 by 5.38%. Similarly, it is above its 200-day moving average of $8.57 by 33.49%. The MACD histogram is -0.13, indicating bearish momentum (MACD Line: -0.30, Signal Line: -0.16).

52-Week Range

$14.39 - $3.47

-20.50% from high · +229.49% from low

Avg Daily Volume

1,492,620

20-day average

100-day avg: 2,112,509

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

-24.34

Price to Book

7.73

EV/EBITDA

-24.86

EPS (TTM)

-$0.37

Beta

0.92

Less volatile than market

Q:How is TRVI valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is TRVI's risk profile compared to the market?
With a beta of 0.92, Trevi Therapeutics, Inc. is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 7.73 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

0.00%

EBITDA

$-51,200,000

Return on Equity

-36.87%

Return on Assets

-23.93%

Q:How profitable and efficient is TRVI's business model?
Profitability metrics are not available for this stock.
Q:What are TRVI's recent growth trends?
Growth data is not available for this stock.

Company Size & Market

Market Cap

$1.5B

Shares Outstanding

128.23M

Book Value/Share

$1.48

Asset Type

EQUITY

Q:What is TRVI's market capitalization and position?
Trevi Therapeutics, Inc. has a market capitalization of $1.5B, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 128.23M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.
Q:How does TRVI's price compare to its book value?
Trevi Therapeutics, Inc.'s book value per share is $1.48, while the current stock price is $11.44, resulting in a price-to-book (P/B) ratio of 7.73. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$21.30

86.19% upside potential

Analyst Recommendations

Strong Buy

2

Buy

8

Hold

0

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for TRVI?
10 analysts cover TRVI with 100% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $21.30 implies 86.2% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on TRVI?
Current analyst recommendations:2 Strong Buy, 8 Buy, 000The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Jan 15, 2026, 02:10 AM

Technical Indicators

RSI (14-day)

43.15

Neutral

50-Day Moving Average

$12.09

-5.38% below MA-50

200-Day Moving Average

$8.57

33.49% above MA-200

MACD Line

-0.30

MACD Signal

-0.16

MACD Histogram

-0.13

Bearish

Q:What does TRVI's RSI value tell investors?
The RSI (Relative Strength Index) for TRVI is currently 43.15, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
Q:How should traders interpret TRVI's MACD and moving average crossovers?
MACD analysis shows the MACD line at -0.30 below the signal line at -0.16, with histogram at -0.13. This bearish crossover indicates downward pressure. The 50-day MA ($12.09) is above the 200-day MA ($8.57), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently between the MAs, suggesting transition.

Indicators last updated: Jan 15, 2026, 12:49 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for TRVI and get notified when the price changes.

Stay Ahead of the Market with Trevi Therapeutics, Inc. Alerts

Set up price alerts for Trevi Therapeutics, Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.